(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 August 2014 (07.08.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/121087 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2014/014175

(22) International Filing Date:
31 January 2014 (31.01.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/759,578 1 February 2013 (01.02.2013) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **DAVIS, Samuel**; 332 West 88th Street, Apt. B2, New York, New York 10024 (US). **SMITH, Eric**; 310 Lexington Avenue, Apt. 4E, New York, New York 10016 (US). **PATEL, Supriya**; 448 Halstead Avenue, Apt. 2C, Mamaroneck, New York 10543 (US). **RAFIQUE, Ashique**; 99 Franklin Avenue, Yonkers, New York 10705 (US).

(74) Agent: **JOHNSON, Mary**; Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTIBODIES COMPRISING CHIMERIC CONSTANT DOMAINS

Construction of chimeric hinge

	Upper Hinge												Lower Hinge							
IgG1 EU numbering	216	217	218	219	220	221	222	223	224	225	226	227								
IgG1 Kabat numbering	225	227	228	232[a] 229[b]	233[a] 230[b]	234[a] 231[b]	235	236	237	238	239	240								
IgG1	E	P	K	S	C	D	K	T	H	T	C	P	IgG2	P	C	P	A	P	P	V	A
IgG4	E	S	K	Y	G	~	~	~	P	P	C	P								
IgG4 EU numbering	216	217	218	-[a] 219[b]	-[a] 220[b]				224	225	226	227	IgG2 EU numbering	228	229	230	231	232	233	234	235
IgG4 Kabat numbering	225	227	228	229	230				237	238	239	240	IgG2 Kabat numbering	241	242	243	244	245	246	247	248

- means no corresponding number reported
~ means no corresponding amino acid
[a] numbering according to the last updated IMGT Scientific Chart (IMGT®, the international ImMunoGeneTics information system®, http://www.imgt.org/IMGTScientificChart/Numbering/Hu_IGHGnber.html, created: 17 May 2001, last updated: 10 Jan 2013)
[b] numbering according to EU index as reported in Kabat, E.A. et al. Sequences of Proteins of Immunological Interest. 5th ed. US Department of Health and Human Services, NIH publication No. 91-3242 (1991)

FIG. 2

(57) Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

WO 2014/121087 A1